BAMBEC TABLET 10mg

Product Information

Registration Status: Active

BAMBEC TABLET 10mg is approved to be sold in Singapore with effective from 1997-06-03. It is marketed by ASTRAZENECA SINGAPORE PTE LTD, with the registration number of SIN09269P.

This product contains Bambuterol 10mg in the form of TABLET. It is approved for ORAL use.

This product is manufactured by ASTRAZENECA AB in SWEDEN, andAstraZeneca Pharmaceutical Co. Ltd in CHINA.

It is a Pharmacy Only Medicine that can be obtained from a pharmacist at a retail pharmacy.

Bambuterol

Description

Bambuterol is a long acting beta-adrenoceptor agonist used in the treatment of asthma. It is a prodrug of terbutaline.

Indication

For the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema.

Mechanism of Action

The pharmacologic effects of bambuterol are at least in part attributable to stimulation through beta-adrenergic receptors (beta 2 receptors) of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic AMP. Increased cyclic AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.

Pharmacokinetics

Absorption
Bioavailability is 20% following oral administration.
Distribution
Metabolism
Hepatic, extensive. Further metabolized to terbutaline by plasma cholinesterase.
Elimination

Active Ingredient/Synonyms

(±)-5-(2-(tert-butylamino)-1-hydroxyethyl)-m-phenylene bis(dimethylcarbamate) | bambutérol | Bambuterol | Bambuterolum | Bambuterol |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank